Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
2.

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509. Epub 2018 Apr 4. No abstract available.

3.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

4.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

5.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

6.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

7.

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.

Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Fahey MT, Jones J, Compston DA, Coles A.

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15. doi: 10.1136/jnnp-2014-307721. Epub 2014 May 21.

PMID:
24849515
8.

Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations.

Pfeffer G, Burke A, Yu-Wai-Man P, Compston DA, Chinnery PF.

Neurology. 2013 Dec 10;81(24):2073-81. doi: 10.1212/01.wnl.0000437308.22603.43. Epub 2013 Nov 6. Review.

9.

Immune competence after alemtuzumab treatment of multiple sclerosis.

McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL.

Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7.

10.

Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive dataset.

Field KM, Drummond KJ, Yilmaz M, Tacey M, Compston D, Gibbs P, Rosenthal MA.

J Clin Neurosci. 2013 Jun;20(6):783-9. doi: 10.1016/j.jocn.2012.09.013. Epub 2013 Apr 29.

PMID:
23639619
11.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
12.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
13.

Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.

Ismail A, Cooper-Knock J, Highley JR, Milano A, Kirby J, Goodall E, Lowe J, Scott I, Constantinescu CS, Walters SJ, Price S, McDermott CJ, Sawcer S, Compston DA, Sharrack B, Shaw PJ.

J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):79-87. doi: 10.1136/jnnp-2012-303326. Epub 2012 Oct 20.

PMID:
23085936
14.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
15.

Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation.

Sajic M, Hunt DP, Lee W, Compston DA, Schweimer JV, Gregson NA, Chandran S, Smith KJ.

PLoS One. 2012;7(2):e30708. doi: 10.1371/journal.pone.0030708. Epub 2012 Feb 16.

16.

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.

Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5.

PMID:
22056965
17.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
18.

Retinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state.

Patani R, Hollins AJ, Wishart TM, Puddifoot CA, Alvarez S, de Lera AR, Wyllie DJ, Compston DA, Pedersen RA, Gillingwater TH, Hardingham GE, Allen ND, Chandran S.

Nat Commun. 2011;2:214. doi: 10.1038/ncomms1216.

19.

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ.

Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21.

PMID:
20659956
20.

Association of the human leucocyte antigen region with susceptibility to Parkinson's disease.

Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, Compston DA, Barker RA, Sawcer SJ, Goris A.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):890-1. doi: 10.1136/jnnp.2008.162883. Epub 2010 May 12.

PMID:
20462916
21.

Initial impact of Australia's National Bowel Cancer Screening Program.

Ananda SS, McLaughlin SJ, Chen F, Hayes IP, Hunter AA, Skinner IJ, Steel MC, Jones IT, Hastie IA, Rieger NA, Shedda S, Compston DJ, Gibbs P.

Med J Aust. 2009 Oct 5;191(7):378-81.

PMID:
19807627
22.

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ.

J Clin Immunol. 2010 Jan;30(1):99-105. doi: 10.1007/s10875-009-9327-3. Epub 2009 Sep 10.

PMID:
19763798
23.

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA.

J Neurol. 2009 Mar;256(3):493-8. doi: 10.1007/s00415-009-0119-8. Epub 2009 Mar 18.

PMID:
19308307
24.

Effects of direct transplantation of multipotent mesenchymal stromal/stem cells into the demyelinated spinal cord.

Hunt DP, Irvine KA, Webber DJ, Compston DA, Blakemore WF, Chandran S.

Cell Transplant. 2008;17(7):865-73.

PMID:
19044212
25.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

26.

Increasing prevalence and incidence of multiple sclerosis in South East Wales.

Hirst C, Ingram G, Pickersgill T, Swingler R, Compston DA, Robertson NP.

J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):386-91. doi: 10.1136/jnnp.2008.144667. Epub 2008 Oct 17.

PMID:
18931003
27.

Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice.

Ananda S, Field KM, Kosmider S, Compston D, Desai J, Lim LC, Barnett FS, Jones IT, Skinner I, Gibbs P.

J Clin Oncol. 2008 Sep 20;26(27):4516-7; author reply 4517-8. doi: 10.1200/JCO.2008.18.7443. No abstract available.

PMID:
18802167
28.

Genetic variation in nitric oxide synthase 2A (NOS2A) and risk for multiple sclerosis.

Barcellos LF, Ramsay PP, Caillier SJ, Sawcer S, Haines J, Schmidt S, Pericak-Vance M, Compston DA, Gabatto P, Hauser SL, Oksenberg JR.

Genes Immun. 2008 Sep;9(6):493-500. doi: 10.1038/gene.2008.41. Epub 2008 Jun 26.

29.

Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis.

Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJ, Giovannoni G, Compston DA, Baker D, Spillantini MG, Chandran S.

Brain. 2008 Jul;131(Pt 7):1736-48. doi: 10.1093/brain/awn119. Epub 2008 Jun 21.

PMID:
18567922
30.

Survival and cause of death in multiple sclerosis: a prospective population-based study.

Hirst C, Swingler R, Compston DA, Ben-Shlomo Y, Robertson NP.

J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1016-21. doi: 10.1136/jnnp.2007.127332. Epub 2008 Feb 26.

PMID:
18303108
31.

Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis.

Hirst C, Ingram G, Swingler R, Compston DA, Pickersgill T, Robertson NP.

J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1137-43. doi: 10.1136/jnnp.2007.133785. Epub 2008 Feb 26.

PMID:
18303106
32.

HLA-DRB1 and multiple sclerosis in Malta.

Dean G, Yeo TW, Goris A, Taylor CJ, Goodman RS, Elian M, Galea-Debono A, Aquilina A, Felice A, Vella M, Sawcer S, Compston DA.

Neurology. 2008 Jan 8;70(2):101-5. Epub 2007 Dec 5.

PMID:
18057318
33.

Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.

Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, Caillier SJ, Ban M, Goris A, Barcellos LF, Lincoln R, McCauley JL, Sawcer SJ, Compston DA, Dubois B, Hauser SL, Garcia-Blanco MA, Pericak-Vance MA, Haines JL; Multiple Sclerosis Genetics Group.

Nat Genet. 2007 Sep;39(9):1083-91. Epub 2007 Jul 29.

PMID:
17660817
34.

Primary spinal cord neurodegeneration in Leber hereditary optic neuropathy.

Jaros E, Mahad DJ, Hudson G, Birchall D, Sawcer SJ, Griffiths PG, Sunter J, Compston DA, Perry RH, Chinnery PF.

Neurology. 2007 Jul 10;69(2):214-6. No abstract available.

PMID:
17620555
35.

Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease.

Goris A, Williams-Gray CH, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Barker RA, Sawcer SJ.

J Neurol. 2007 Jul;254(7):846-8.

PMID:
17431704
36.

Familial effects on the clinical course of multiple sclerosis.

Hensiek AE, Seaman SR, Barcellos LF, Oturai A, Eraksoi M, Cocco E, Vecsei L, Stewart G, Dubois B, Bellman-Strobl J, Leone M, Andersen O, Bencsik K, Booth D, Celius EG, Harbo HF, Hauser SL, Heard R, Hillert J, Myhr KM, Marrosu MG, Oksenberg JR, Rajda C, Sawcer SJ, Sørensen PS, Zipp F, Compston DA.

Neurology. 2007 Jan 30;68(5):376-83.

PMID:
17261686
37.

No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening.

Goris A, Williams-Gray CH, Foltynie T, Compston DA, Barker RA, Sawcer SJ.

Am J Hum Genet. 2006 Jun;78(6):1088-90; author reply 1092-4. No abstract available.

38.

Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.

Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA.

J Neurol Neurosurg Psychiatry. 2006 May;77(5):665-7.

39.

No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease.

Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA.

Mov Disord. 2006 May;21(5):731-2. No abstract available.

PMID:
16552758
40.

Astrocytes promote neurogenesis from oligodendrocyte precursor cells.

Gaughwin PM, Caldwell MA, Anderson JM, Schwiening CJ, Fawcett JW, Compston DA, Chandran S.

Eur J Neurosci. 2006 Feb;23(4):945-56.

PMID:
16519659
41.

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ.

Eur J Immunol. 2005 Nov;35(11):3332-42.

42.

The BDNF-Val66Met polymorphism: implications for susceptibility to multiple sclerosis and severity of disease.

Lindquist S, Schott BH, Ban M, Compston DA, Sawcer S, Sailer M.

J Neuroimmunol. 2005 Oct;167(1-2):183-5.

PMID:
16046000
43.

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA.

J Neurol. 2006 Jan;253(1):98-108. Epub 2005 Jul 27.

PMID:
16044212
44.

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA.

Neurology. 2005 Apr 12;64(7):1144-51.

PMID:
15824338
45.

Updated results of the United Kingdom linkage-based genome screen in multiple sclerosis.

Hensiek AE, Roxburgh R, Smilie B, Coraddu F, Akesson E, Holmans P, Sawcer SJ, Compston DA.

J Neuroimmunol. 2003 Oct;143(1-2):25-30.

PMID:
14575910
46.

Task specific focal dystonia: a presentation of spinocerebellar ataxia type 6.

Muzaimi MB, Wiles CM, Robertson NP, Ravine D, Compston DA.

J Neurol Neurosurg Psychiatry. 2003 Oct;74(10):1444-5. No abstract available.

47.

Osteopontin gene and clinical severity of multiple sclerosis.

Hensiek AE, Roxburgh R, Meranian M, Seaman S, Yeo T, Compston DA, Sawcer SJ.

J Neurol. 2003 Aug;250(8):943-7.

PMID:
12928913
48.

Searching for needles in haystacks-the genetics of multiple sclerosis and other common neurological diseases.

Hensiek AE, Sawcer SJ, Compston DA.

Brain Res Bull. 2003 Aug 15;61(3):229-34. Review.

PMID:
12909292
49.

Tuberous sclerosis presenting in late adult life.

Zarei M, Collins VP, Chandran S, Valler D, Higgins JN, Compston DA, Yates JR.

J Neurol Neurosurg Psychiatry. 2002 Oct;73(4):436-8.

50.

Continuing optic nerve atrophy following optic neuritis: a serial MRI study.

Hickman SJ, Brierley CM, Brex PA, MacManus DG, Scolding NJ, Compston DA, Miller DH.

Mult Scler. 2002 Aug;8(4):339-42.

PMID:
12166505

Supplemental Content

Loading ...
Support Center